Rather, SGLT2 inhibitors were associated with a lower risk of hyperkalemia, particularly in patients with diabetic nephropathy who concurrently received RAS inhibitors or MRAs [11]. The gene discussed is SLC5A2; the disease is diabetic kidney disease.